Study S002544

Evaluation of Optimal Dosing Conditions for GLP-1 Analogue NNC0113-0987 When Administered Orally in Healthy Male Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02094521
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1
Masking: NONE
Status: COMPLETED
Enrollment: 122
Start: 2014-03
Primary completion: 2014-07
Lead sponsor: Novo Nordisk A/S
Conditions: Diabetes; Healthy
Interventions: DRUG:NNC0113-0987
Results posted: FALSE
Secondary identifiers: EUDRACT_NUMBER:2012-003855-13; OTHER:U1111-1133-7097

Registered primary outcomes

Area under the NNC0113-0987 plasma concentration time curve [From time 0 to 24 hours after the 10th dosing]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.